Results 231 to 240 of about 75,548 (336)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

British Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen, Tamás Kovács, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Intrinsic PDL1 Signaling Modulates TGFBI‐Mediated Growth Suppression in Lung Adenocarcinoma

Cancer Science, EarlyView.
Programmed death ligand 1 (PDL1) is known for suppressing T‐cell immunity, but its intrinsic role in oncogenesis remains unclear. This study demonstrates that PDL1 expression in lung adenocarcinoma (ADC) inhibits tumor cell growth by reducing FAK activation and regulating the CITED2‐p21CIP1 axis, leading to cell growth arrest.
Thi Thanh Nha Nguyen, Pei‐Yu Chen, Ming‐Yi Zheng, Ting‐Kuang Lin, Chun‐Chao Wang, Yuh‐Min Chen, Yu‐Ting Chou   +6 more
wiley   +1 more source

DNA Methylation in Ovarian and Endometrial Cancers: Predictive and Mechanistic Roles in PARP Inhibitor and ICI Response

Cancer Science, EarlyView.
Cancer treatment is shifting from an organ‐based framework to one driven by biological phenotypes, and DNA methylation is increasingly recognized as an important factor that governs tumor behavior beyond genetic mutations. In gynecologic cancers, BRCA1 and MLH1 promoter methylation–associated homologous recombination deficiency and mismatch repair ...
Shuhei Kitamura, Ayumi Taguchi, Kana Tamai, Yoko Yamamoto, Anh Quynh Duong, Daisuke Yoshimoto, Ayako Mori, Aya Ishizaka, Saki Tsuchimochi, Kenbun Sone, Masahito Kawazu, Katsutoshi Oda, Yasushi Hirota   +12 more
wiley   +1 more source

T cell-engaging CD276xCD3 bispecific antibody for treatment of endometrial cancer. [PDF]

J Transl Med
Greiner SM, Mauermann J, Lutz MS, Hagelstein I, Hartkopf AD, Zekri L, Jung G, Salih HR, Märklin M.   +8 more
europepmc   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

Clinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Prognostic significance of trophoblastic differentiation and β-hCG secretion in somatic malignancies of uterine corpus: A systematic review with survival analysis. [PDF]

Oncoscience
Mangla M, Palo S, Kaur H, Kanikaram PK, Rahiman EA.   +4 more
europepmc   +1 more source

Significance of Exogenous Estradiol on Plasma Cortisol and Salivary Cortisol During Adrenocorticotropic Hormone Stimulation in Women With Pituitary Insufficiency

Clinical Endocrinology, EarlyView.
ABSTRACT Objective Oral estrogens increase the levels of cortisol binding globulin (CBG) potentially affecting test results for adrenal insufficiency. The objective was to evaluate the influence of oral and transdermal estradiol on total plasma (p) and salivary cortisol in hypogonadal women with secondary adrenal insufficiency or at risk of developing ...
Laura S. Aagaard, Jesper Krogh, Signe Perlman, Marianne Klose, Mikkel Andreassen   +4 more
wiley   +1 more source

From guidelines to clinical practice: the impact of sentinel lymph node mapping on surgical management in endometrial cancer. [PDF]

J Med Life
Blidaru A, Anca-Stanciu MB, Manu A, Coroleucă BC, Coroleucă CA, Brătilă E.   +5 more
europepmc   +1 more source

PMS2 c.2117del (p.Lys706Serfs*19) is the Most Frequent Cancer‐Associated Founder Pathogenic Variant in the French‐Canadian Population of Quebec, Canada

Clinical Genetics, EarlyView.
Using haplotype analysis, we characterized PMS2 c.2117del, identified in 22 families, as a founder variant in the French‐Canadian population of Quebec. It is the most frequent cancer‐associated founder variant in French‐Canadians, with over‐representation in five regions of Quebec. The variant contributed to colorectal and endometrial cancer incidence.
Anne‐Laure Chong, Alejandro Mejia‐Garcia, Supriya Behl, Zaki El Haffaf, Sébastien Chénier, Bruno Maranda, Valérie Désilets, Sébastien Lévesque, Lysanne Castonguay, Anne‐Marie Mes‐Masson, Sylvie Giroux, François Rousseau, Nancy Hamel, George Chong, Simon Gravel, William D. Foulkes   +15 more
wiley   +1 more source

SCENE: Signature Collection for Endometrial Cancer Prognosis. [PDF]

J Cell Mol Med
Dugo E, Piva F, Giulietti M, Giannella L, Ciavattini A.   +4 more
europepmc   +1 more source